yes especially since on average the DAA's (I believe) trend downward to a range of about 10% with cirrhosis. Anyone have other info on this predictor ? Like the validity & reliabilty - given the paucity of data on some of the DAAs (like Daclatasvir) and apparently low subject numbers in many of the trials. Any multivariate statisticians on board ?
PS you need a red hat & shoes, with your red polymer cast. Tres chic.